Home / Market News / $EBS
benzinga Corporate Catalyst Impact 55/100 ● neutral

HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $10

Aug 10, 2026, 10:13 AM UTC · Primary ticker $EBS

This filing discloses that HC Wainwright & Co. has lowered its price target for Emergent BioSolutions (EBS) from $12 to $10, while maintaining a 'Buy' rating. This indicates a slightly less optimistic outlook from the analyst, though the continued 'Buy' rating suggests underlying confidence in the company's long-term prospects.

HC Wainwright & Co. analyst Raghuram Selvaraju has adjusted the price target for Emergent BioSolutions (EBS) from $12 to $10, while reiterating a 'Buy' rating. This action signals a recalibration of the analyst's valuation for EBS, likely due to updated financial models, market conditions, or company-specific news not detailed in this filing. For traders, this represents a short-term negative sentiment shift as the perceived upside potential has decreased. However, the maintained 'Buy' rating suggests that the analyst still sees value in the stock, implying that the long-term outlook might remain positive despite the near-term adjustment. The key risk for traders is potential downward pressure on EBS's stock price following this news, while the opportunity lies in assessing if the new price target accurately reflects the company's fundamentals or if the market overreacts.

$EBS negative Price target lowered
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.